Tyler Seibert MD PhD
@TylerSbrt
Followers
3K
Following
29K
Media
1K
Statuses
16K
#radonc and #cancer scientist @UCSanDiego. Quantitative MRI. Genetic risk. https://t.co/h6i5eUrPMk
San Diego, CA
Joined November 2019
🏃🏼 by 💧 Any recent 🚶🏻♀️🏃🏽♀️🚴🏼 photos from my oncology friends around the 🌍 ? @VedangMurthy @aadel_chaudhuri @cwspeers @andreasroder1 @HenningWillers @brookmans76 @_ShankarSiva @ResearchWyatt @ProfAJChalmers @shiv_smith @scserendipity1 @SimonMDLord @RenuEapen @AlisonBirtle
37
10
93
"You should be intellectually flexible and go where the science is needing you." Fresh from receiving his Nobel Prize medal and diploma, 2025 chemistry laureate Omar Yaghi visited a high school to share his research journey and advice with students. He described how he and his
11
48
203
🚨 Can MRI replace confirmatory biopsy in #prostatecancer active surveillance? 💡Data in @JAMAOnc from ~1,900 patients says not yet. 👉NPV of negative MRI for GG≥2 only ~75% 👉Better for ruling out GG≥3, but misses clinically significant disease 👉Highest reassurance when
2
33
88
Que el próximo año nos traiga salud, logros compartidos y nuevas oportunidades para seguir creciendo juntos. ¡Que 2026 esté lleno de inspiración, esperanza y éxito para cada uno de ustedes y sus familias! #SOMERA #Rt #Radioterapia #RadioOncología #Salud #FelizNavidadParaTodos
0
2
3
Early favorable PSA response is a strong predictor of OS in mHSPC. But should we wait 6 months to see how the PSA responds or we build a tool that can predict favorable PSA response? https://t.co/CdaocegKZy
nature.com
Nature Communications - There is a need for an easy-to-use clinical tool, that could predict favorable early PSA response and subsequently enhance early risk stratification, as well as guide...
7
20
56
And thank you so much @PCF_Science for your support and investment in young investigators like us. Without your support this would not have been possible.
0
2
2
A year ago today we lost @felixfengmd and I think of him every day. We know you’re up there cracking a joke, dreaming up the next big paper or or grant or company, having a milk tea, or about to call us at an inopportune time about something actually quite important.
2
8
73
Very well said @CChuMD thanks for sharing this so well written obituary! I worked together with the tremendous Felix Feng 4 years at @UMich his amazing impact/legacy stays and keep us all very inspired! @MaryFengMD @koshkin85 @DrTFriedlander @DrRanaMcKay @montypal @neerajaiims
A year ago today we lost @felixfengmd and I think of him every day. We know you’re up there cracking a joke, dreaming up the next big paper or or grant or company, having a milk tea, or about to call us at an inopportune time about something actually quite important.
2
2
20
53 #NHS1000miles walked this week by the 🌊 some gorgeous sunrises. Looking forward to seeing everyone’s active pics 🥰
8
3
26
Congratulations to Oleksandr Frei and collaborators in the Psychiatric Genomics Consortium on this comprehensive cross-disorder study in @Nature, showing that 14 psychiatric disorders share a broad genetic foundation captured by 5 core genomic factors https://t.co/oe0IM2SoHx
nature.com
Nature - Genomic analyses applied to 14 childhood- and adult-onset psychiatric disorders identifies five underlying genomic factors that explain the majority of the genetic variance of the...
0
1
4
@VedangMurthy @NickJames2021 @APCCC_Lugano @piet_ost @ChadTangMD @a_dalpra @Silke_Gillessen @TylerSbrt @Mat_Guc @NicholasZaorsky @PBlanchardMD @DrAndrewLoblaw @seanmmcbride @ZilliThomas @_ShankarSiva @AmarUKishan @alison_tree @DrPaulNguyen Nice work my friend 🙏 Partially confirming the rationale of Gundem et al. Treat the primary to avoid 2nd wave from the DIL, treat the Mets to also avoid 2nd wave from the '' baseline '' Mets. https://t.co/KyZtpu9XLO
nature.com
Nature - Gunes Gundem et al. have mapped the subclonal composition of human prostate tumours and their metastases, thus establishing the evolutionary history behind the development and spread of...
3
3
21
Why this matters? MDT trials assume that treating visible mets influence outcomes. Our data suggest that baseline mets are the first to break through, MDT aims to interrupt this pattern This pattern provides biological rationale for ongoing MDT trials. e.g STAMPEDE 2
1
3
17
Our new study in @Nature @pcan_journal We report progression patterns in de novo oligo HSPC staged with PSMA-PET, treated with prostate but no MDT This allowed us to observe the natural history of PSMA defined oligometastatic disease. Fill paper link https://t.co/HGZ9jIUP0Q
11
34
80
https://t.co/P9gZ7XB067
@harold_collard: “The NIH recently ended its SBIR and STTR program. This is a big deal - here's why.”
linkedin.com
The NIH recently ended its SBIR and STTR program. This is a big deal - here's why. NIH’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards provide...
0
2
10
🇫🇷 GETUG-AFU 30 phase 2 randomized trial : - For patients with pathological high-risk MIBC, adjuvant RT is Safe and Feasible - All patients received the full prescribed dose without early termination or discontinuation. - Low rates of Gi / Gu acute toxicity were observed!
3
25
60
Worth a listen!!🎧 Two of my favorite collaborators to talk #ProstateCancer with meet virtually and have a great discussion about new results from the ProtecT trial may change how we think about this disease @NikiSushentsev @dr_coops @urotoday @PCF_Science
Many thanks @dr_coops and @urotoday for inviting me to chat about the recent ProtecT biopsy review paper in @JAMAOnc! This conversation will continue through our replies to Letters and upcoming ProtecT radical prostatectomy review - watch this space 👀 https://t.co/zyzniN08Zj
0
2
7
PUBLISHED! Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 @PCFnews Coffey-Holden #ProstateCancer Academy Meeting! Read up on all this exciting new research! @AndreaMiyahira @soulehoward1 @SaulPriceman @tranpt21 @DrRanaMcKay
https://t.co/AOF48C4rvu
0
5
11
@TylerSbrt @PaulSargos @aadel_chaudhuri @cwspeers @andreasroder1 @brookmans76 @_ShankarSiva @ResearchWyatt @scserendipity1 @SimonMDLord @RenuEapen @AlisonBirtle @mrsprostate @alison_tree @MariamAboian @sophia_kamran @lauren_henke @HimanshuNagarMD @JuanMiguelPechL @ethansgrumps @swoo_rad @Prof_Nick_James Meanwhile in London baby 🎅🎄🎉
1
1
7
@LondonProstate1 @TylerSbrt @vipulpatelmd Yes- though a lot of that focus is on better continence at 2-6 mos postop rather than long-term. (Eg retzius sparing) And there’s clearly a need for techniques that community surgeons can adopt to improve from a much lower baseline.
1
1
3
The dose–volume constraints generated here now form the foundation of the upcoming Prospective PROTO-PRIME prospective trial, which will compare SBPT vs SBRT for HR #ProstateCancer A new chapter for pelvic ultrahypofractionation begins. @RadOncTMC @ApolloProton @TataMemorial
0
2
11